Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRLX301
- Development stage
- Phase 2
- Lead developer
- Daré Bioscience
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CRLX301 is a nanoparticle-drug conjugate (NDC) containing docetaxel, a second-generation taxane analog. It is designed to concentrate in tumors and slowly release its anti-cancer payload inside tumor cells while sparing healthy tissue. The formulation uses a cyclodextrin-polyethylene glycol co-polymer (CDP) to which docetaxel is covalently conjugated. In preclinical studies, CRLX301 showed enhanced drug accumulation in tumor tissue and greater tumor growth suppression in murine models compared to docetaxel, delivering up to 10 times more docetaxel into tumors. It exhibited pharmacokinetic advantages over docetaxel including higher retention of drug in plasma, slower clearance, and controlled slow release of docetaxel from the carrier[1][2][4][5].
- Other names
- docetaxel-loaded nanopharmaceutical CRLX301
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CRLX301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRLX301.